TABLE 2.
Body mass index (BMI) in kg/m2, eating disorder examination questionnaire (EDE‐Q), clinical impairment assessment (CIA), and brief symptom inventory (BSI) in patients with anorexia nervosa treated during and before (controls) the COVID‐19 pandemic
| Completer analysis | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | End of treatment | 20‐week follow‐up | |||||||
| Mean and SD | Patients exposed to pandemic (n = 43) | Controls (n = 50) | Patients exposed to pandemic (n = 43) | Controls (n = 50) | Patients exposed to pandemic (n = 28) | Controls (n = 38) | Repeated measures ANOVA | ||
| Time; partial eta squared | Time X group; partial eta squared | Group; partial eta squared | |||||||
| BMI | 15.0 (1.9) | 14.8 (2.0) | 19.9 (1.1) | 19.8 (1.3) | 18.8 (2.5) | 19.4 (1.8) | 40.35b; 0.390 | 1.53; 0.024 | 0.22; 0.004 |
| EDE‐Q global score | 3.9 (1.2) | 4.1 (1.3) | 2.2 (1.1) | 1.9 (1.3) | 2.3 (1.4) | 1.2 (1.1) | 8.18b; 0.118 | 3.76a; 0.058 | 8.39a; 0.121 |
| CIA global score | 33.9 (11.7) | 37.3 (8.7) | 18.9 (10.8) | 15.6 (12.3) | 21.9 (13.2) | 10.9 (10.6) | 23.54b; 0.278 | 7.44b; 0.109 | 14.57b; 0.193 |
| BSI global score | 1.9 (0.8) | 2.3 (0.7) | 1.1 (0.8) | 1.1 (0.7) | 1.3 (0.8) | 0.8 (0.7) | 51.71b; 0.459 | 5.98b; 0.089 | 10.09b; 0.142 |
| N (%) | Chi‐squared test; p value end of treatment | Chi‐squared test; p value 20‐week follow‐up | ||||||
|---|---|---|---|---|---|---|---|---|
| BMI ≥ 18.5 | — | — | 40 (93.0%) | 46 (92.0%) | 17 (60.7%) | 26 (68.4%) | 0.03; .852 | 0.42; .516 |
| BMI ≥ 18.5 and EDE‐Q global score <2.77 | — | — | 23 (53.5%) | 35 (70.0%) | 15 (53.6%) | 25 (65.8%) | 1.51; .218 | 1.01; .315 |
| Intention‐to‐treat analysis–multiple imputation procedure | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | End of treatment | 20‐week follow‐up | Repeated‐measures ANOVA | ||||||
| Mean and SE | Patients exposed to pandemic (n = 57) | Control patients (n = 57) | Patients exposed to pandemic (n = 57) | Control patients (n = 57) | Patients exposed to pandemic (n = 57) | Control patients (n = 57) | Time; partial eta squared | Time X Group; partial eta squared | Group; partial eta squared |
| BMI | 15.0 (0.3) | 14.8 (0.2) | 19.8 (0.2) | 19.7 (0.2) | 18.5 (0.5) | 19.5 (0.5) | 146.3b; 0.191 | 9.29b; 0.015 | 2.87; 0.005 |
| EDE‐Q global score | 4.0 (0.2) | 4.1 (0.1) | 2.1 (0.1) | 1.9 (0.2) | 2.1 (0.2) | 1.4 (0.2) | 82.49b; 0.118 | 23.56b; 0.037 | 34.48b; 0.053 |
| CIA global score | 34.6 (1.6) | 37.8 (1.1) | 18.3 (1.5) | 16.2 (1.8) | 18.8 (2.2) | 13.2 (2.0) | 152.33b; 0.199 | 26.10b | 38.21b; 0.058 |
| BSI global score | 1.89 (0.1) | 2.25 (0.1) | 1.1 (0.1) | 1.1 (0.1) | 1.1 (0.1) | 0.8 (0.1) | 309.87b; 0.335 | 21.61b; 0.034 | 27.33b; 0.042 |
| N (%) | Chi‐squared test; p value end of treatment | Chi‐squared test; p value 20‐week follow‐up | ||||||
|---|---|---|---|---|---|---|---|---|
| BMI ≥18.5, | — | — | 52 (91.2%) | 52 (91.2%) | 38 (66.7%) | 31 (54.4%) | 1.00; — | 1.80; .180 |
| BMI ≥18.5 and EDE‐Q global score <2.77 | — | — | 35 (61.4%) | 39 (68.4%) | 29 (50.9%) | 37 (64.9%) | 0.62; .432 | 2.30; .129 |
Note: Data from completer and intention‐to‐treat analysis. The propensity score was used as a confounding variable. a p < .01 and b p < .001.